Chromatics Color Solutions (CCSI) Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) announced today that in connection with its previously announced delay in filing its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”), it received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") on March 21, 2023, stating that because the Company has not yet filed the Form 10-K, it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").

This notification has no immediate effect on the listing of the Company's shares on Nasdaq.

The Notice states that, under Nasdaq rules, the Company has 60 calendar days to submit to Nasdaq a plan (the “Plan”) to regain compliance with Nasdaq’s continued listing requirements (the “Plan Deadline”). If the Plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to regain compliance. The Company can also regain compliance with Nasdaq’s continued listing requirements at any time prior to the Plan Deadline by filing the Form 10-K, along with any subsequent periodic reports that may become due, and by continuing to comply with Nasdaq’s other continued listing requirements.

The Company intends to file the Form 10-K with the SEC on or before March 31, 2023 and in any event, substantially in advance of the Plan Deadline.

The Company has not as of the date hereof identified any material changes to the unaudited, preliminary financial data furnished in the Earnings 8-K as of or for the year ended December 31, 2022.

The Company is still finalizing its financial closing process for the year ended December 31, 2022 and the Company’s audited financial results as of and for the year ended December 31, 2022 are not yet available. The unaudited, preliminary financial data for the year ended December 31, 2022 included in Earnings 8-K were prepared by, and is the responsibility of, the Company’s management. The Company’s auditor has not audited, reviewed, compiled or applied agreed-upon procedures with respect to such preliminary financial data. Accordingly, the Company’s auditor does not express an opinion or any other form of assurance with respect thereto. Upon completion of its financial closing procedures, the Company’s audited financial results may differ materially from its preliminary estimates.

You May Also Be Interested In

• Belite Bio (BLTE) Announces $25 Million Registered Direct Offering
• AZZ, Inc. (AZZ) Announces Proposed 4M Share Offering
• HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab